INKT (MiNK Therapeutics) Accumulated other comprehensive income (loss) : $-0.66 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. MiNK Therapeutics's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $-0.66 Mil.

MiNK Therapeutics's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2024 ($-0.67 Mil) to Dec. 2024 ($-0.63 Mil) but then declined from Dec. 2024 ($-0.63 Mil) to Mar. 2025 ($-0.66 Mil).

MiNK Therapeutics's annual Accumulated other comprehensive income (loss) declined from Dec. 2022 ($-0.29 Mil) to Dec. 2023 ($-0.43 Mil) and declined from Dec. 2023 ($-0.43 Mil) to Dec. 2024 ($-0.63 Mil).

MiNK Therapeutics Accumulated other comprehensive income (loss) Historical Data

The historical data trend for MiNK Therapeutics's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics Accumulated other comprehensive income (loss) Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-1.52

-0.63

-0.29

-0.43

-0.63

MiNK Therapeutics Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															-0.39	-0.61	-0.67	-0.63	-0.66

MiNK Therapeutics Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

MiNK Therapeutics Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010